Leukemia News

The Leukemia & Lymphoma Society’s therapy acceleration program announced five investments intended to hasten development of immunotherapies to treat blood cancers.

Six early-career investigators received NCCN Foundation Young Investigator Awards.

The FDA granted orphan drug designation to CA-4948 for treatment of acute myeloid leukemia and myelodysplastic syndrome, according to the agent’s manufacturer.

Patients with active chronic lymphocytic leukemia or multiple myeloma mounted lower antibody responses to mRNA COVID-19 vaccination than healthy individuals, according to data from two reports published in Blood.

Going through cancer during transitional adolescent and young adult years can present additional social, financial and mental health challenges that add to the stressors of diagnosis and treatment.

Working night shifts may interfere with natural 24-hour rhythms in the activity of certain genes related to cancer, leading to increased cancer risk, according to a study published in the Journal of Pineal Research.

Kite Pharma submitted a supplemental biologics license application to the FDA for brexucabtagene autoleucel to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to the agent’s manufacturer.

Steroids are commonly used to mitigate severe treatment-related adverse events associated with chimeric antigen receptor T-cell therapy.

Caloric restriction through diet and exercise appeared to enhance the efficacy of chemotherapy among young patients with B-cell acute lymphoblastic leukemia, according to results of the IDEAL study published in Blood Advances.

The FDA expanded the approval of daunorubicin and cytarabine to include the treatment of children aged at least 1 year with newly diagnosed therapy-related acute myeloid leukemia, according to a manufacturer-issued press release.